Amneal Pharmaceuticals Capital Expenditures (CapEx) Growth & History (AMRX)
Amneal Pharmaceuticals's capital expenditures (capex) was $70.1M for fiscal 2025.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $70.1M | $18.1M | +34.93% |
| 2024 | 2024-12-31 | $51.9M | $8.7M | +20.15% |
| 2023 | 2023-12-31 | $43.2M | −$3.2M | −6.88% |
| 2022 | 2022-12-31 | $46.4M | −$1.3M | −2.77% |
| 2021 | 2021-12-31 | $47.7M | −$8.7M | −15.44% |
| 2020 | 2020-12-31 | $56.4M | $9.3M | +19.64% |
| 2019 | 2019-12-31 | $47.2M | −$35.9M | −43.22% |
| 2018 | 2018-12-31 | $83.1M | −$11.7M | −12.33% |
| 2017 | 2017-12-31 | $94.8M | −$28.0M | −22.80% |
| 2016 | 2016-12-31 | $122.8M | — | — |
Amneal Pharmaceuticals quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $30.7M | $7.9M | +34.46% |
| Q1 2026 | 2026-03-31 | $8.2M | −$5.0M | −37.89% |
| Q4 2025 | 2025-12-31 | $21.8M | $6.6M | +43.67% |
| Q3 2025 | 2025-09-30 | $12.3M | −$4.6M | −27.42% |
| Q2 2025 | 2025-06-30 | $22.8M | $12.2M | +114.85% |
| Q1 2025 | 2025-03-31 | $13.2M | $4.0M | +43.10% |
| Q4 2024 | 2024-12-31 | $15.2M | $5.3M | +53.62% |
| Q3 2024 | 2024-09-30 | $16.9M | $5.3M | +45.33% |
| Q2 2024 | 2024-06-30 | $10.6M | −$1.4M | −11.47% |
| Q1 2024 | 2024-03-31 | $9.2M | −$490,000 | −5.06% |
| Q4 2023 | 2023-12-31 | $9.9M | −$1.6M | −13.96% |
| Q3 2023 | 2023-09-30 | $11.7M | −$7.4M | −38.95% |
| Q2 2023 | 2023-06-30 | $12.0M | $7.0M | +137.73% |
| Q1 2023 | 2023-03-31 | $9.7M | −$1.1M | −10.24% |
| Q4 2022 | 2022-12-31 | $11.5M | −$6.0M | −34.47% |
| Q3 2022 | 2022-09-30 | $19.1M | $8.5M | +79.42% |
| Q2 2022 | 2022-06-30 | $5.0M | −$2.8M | −35.34% |
| Q1 2022 | 2022-03-31 | $10.8M | −$983,000 | −8.35% |
| Q4 2021 | 2021-12-31 | $17.5M | −$12.0M | −40.75% |
| Q3 2021 | 2021-09-30 | $10.6M | −$348,000 | −3.17% |
| Q2 2021 | 2021-06-30 | $7.8M | −$743,000 | −8.69% |
| Q1 2021 | 2021-03-31 | $11.8M | $4.4M | +59.85% |
| Q4 2020 | 2020-12-31 | $29.5M | $25.0M | +553.82% |
| Q3 2020 | 2020-09-30 | $11.0M | −$2.0M | −15.67% |
| Q2 2020 | 2020-06-30 | $8.6M | −$3.1M | −26.54% |
| Q1 2020 | 2020-03-31 | $7.4M | −$10.6M | −59.04% |
| Q4 2019 | 2019-12-31 | $4.5M | −$15.5M | −77.44% |
| Q3 2019 | 2019-09-30 | $13.0M | −$13.4M | −50.75% |
| Q2 2019 | 2019-06-30 | $11.6M | −$5.5M | −31.93% |
| Q1 2019 | 2019-03-31 | $18.0M | −$1.5M | −7.75% |
| Q4 2018 | 2018-12-31 | $20.0M | — | — |
| Q3 2018 | 2018-09-30 | $26.5M | $10.9M | +70.29% |
| Q2 2018 | 2018-06-30 | $17.1M | — | — |
| Q1 2018 | 2018-03-31 | $19.5M | — | — |
| Q3 2017 | 2017-09-30 | $15.5M | — | — |
Amneal Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Amneal Pharmaceuticals's capital expenditures (capex) increased from $56.4M to $70.1M, a change of $13.6M. The latest reported quarter, Q2 2026, shows $30.7M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amneal Pharmaceuticals source filings ↗